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Abstract  
 
Background Eosinophilic fasciitis is a rare scleroderma-like illness. The clinical 
spectrum of the disease has evolved since its initial description. 
Methods We identified all patients diagnosed with eosinophilic fasciitis over the 
past 10 years at our scleroderma clinic. Demographics, disease pattern, 
serologies, tissue pathology and reponse to treatment were all recorded.  
Results Twelve patients with eosinophilic fasciitis were identified in our clinic 
over the past 10 years. The mean age at diagnosis was 49.8 ± 9.8 years, with 
nine female and three male patients.The first symptoms were noticed at an 
average of 8.8 ± 6.1 months before diagnosis. The mean initial absolute 
peripheral blood eosinophil count was 1188 ± 1059 cells/L. Two patients had a 
monoclonal gammopathy, and two had positive ANA titers. All patients received 
corticosteroids, 10 of whom received the equivalent dose of > 20 mg/day of 
prednisone for more than a month. Five patients received hydroxychloroquine, 
two received methotrexate, one received cyclosporine, one received topical 
tacrolimus, and one received sulfasalazine. At a mean follow up of 17.6 months 
(range 2–94 months), 8 patients had a good response to treatment, 2 patients 
had no effect, and 2 patients had a poor response to treatment.  
Conclusion High dose corticosteroid treatment lasting longer than a month with 
or without an immunosuppressive agent helped most patients with eosinophilic 
fasciitis, best results seen in those patients who were initiated treatment early on 
after their first symptoms.  
 
Introduction  
 
Eosinophilic fasciitis is a scleroderma-like syndrome first described in 1974 by 
Shulman in patients with diffuse fasciitis and eosinophilia.
1
 The clinical 
spectrum of this disease has broadened since its first description, as more 
patients are recognized and diagnosed. Eosinophilic fasciitis is a rare disorder 
with varying clinical presentations, making its clinical definition challenging.
2,3 
 
Patients with eosinophilic fasciitis typically report swelling and induration of the 
arms and legs with skin thickening. The usual stages of the disease progress 
from edema of the extremities, to peau d’orange with hyperpigmentation, to 
woody induration with skin tightness. Localized morphea, defined as 
inflammation localized to the reticular dermis and superficial panniculus, has 
been reported. Synovitis and contractures may also be present. Some patients 
have presented with rapidly progressive muscle weakness with associated pain 
and stiffness of the extremities.
2
 A variety of extracutaneous manifestations have 
been reported including arthritic, pulmonary,
 
hematologic, and neoplastic.
4–6
 The 
diagnosis of eosinophilic fasciitis may be delayed, as it has overlapping features 
of other diseases. Scleroderma, polymyositis, hypereosinophilic syndrome, and 
Churg-Strauss vasculitis may all be in the differential diagnosis for a patient 
presenting with eosinophilic fasciitis.  
 
Diagnosis is made by a full thickness skin to muscle biopsy, showing 
inflammation and thickening of collagen bundles in the superficial muscle fascia 
with infiltration of lymphocytes and plasma cells. Eosinophils are occasionally 
seen on biopsy but are not necessary to make the diagnosis. More recent -studies 
have been conducted using MRI for the diagnosis of eosinophilic fasciitis.
7–9
 In a 
retrospective study involving 6 patients, MRI was able to detect fascial thickening 
and signal abnormalities in patients with eosinophilic fasciitis at the time of 
diagnosis
7
. Laboratory analysis for eosinophilic fasciitis typically reveals an 
elevated sedimentation rate, peripheral eosinophilia, and 
hypergammaglobulinemia. The degree of eosinophilia does not correlate with 
disease severity and laboratory results are not helpful in following disease 
activity.
2
 Some patients have shown normalizing laboratory results with 
persistent clinical evidence of eosinophilic fasciitis.
2,7  
 
 
The etiology of eosinophilic fasciitis is uncertain. Reports of extreme physical 
exertion as well as ingestion of certain pharmaceuticals such as l-tryptophan and 
statins have been suggested to have a pathogenic role.
2,10–12
 Other potential 
triggers that have been suggested are trauma, arthropod bites and borrelliosis.
13–
17  
 
 
No clear consensus exists regarding the demographics of eosinophilic fasciitis. 
The mean age of onset has consistently been found to be between 40 and 50 
years of age with a wide range reported from early childhood to the elderly.
2,3
 It 
remains unclear whether race and family history are risk factors in developing 
eosinophilic fasciitis.  
 
 
The mainstay of therapy for eosinophilic fasciitis has largely been corticosteroid 
therapy, although multiple drug regiments have been tried. High-dose 
corticosteroids have shown some efficacy, although steroid-refractory cases have 
been documented. Cyclosporine, hydroxychloroquine, cimetidine, azathioprine, 
and d-penicillamine have all been used for the treatment of eosinophilic 
fasciitis.
2,3,18,19
 These drugs showed variable results and were often used in 
steroid-refractory cases. Recent work has also suggested the potential use of 
antitumor necrosis alpha inhibitors, such as infliximab, to manage resistant 
cases not responsive to typical therapy.
20 
Evaluating the response to treatment 
can be complicated since the natural history of the disease can involve 
spontaneous remission
2
. Lastly photochemotherapy has also been used with 
some success.
21,22  
 
 
Sample size remains a limiting factor in studying eosinophilic fasciitis. The 
disease is rare and the incidence is not known. More data is needed to determine 
the etiology of the disease and its demographic distribution. More information 
needs to be gained in the treatment of the disease, particularly in steroid-
refractory cases. In this study, we attempt to gain more information regarding 
demographics, risk factors, disease patterns and response to treatment in 12 
patients who presented to our scleroderma clinic over a 10 years span. Our goal 
is to help clarify these parameters of eosinophilic fasciitis in which there have 
been few answers due to the small patient population.  
Methods  
Employing a retrospective chart review, we looked at all patients who were seen 
at our scleroderma clinic within a 10 year span that had a diagnosis of 
eosinophilic fasciitis. A total of 12 patients were identified with eosinophilic 
fasciitis during this time period. These patients were diagnosed clinically by 
rheumatologists at the scleroderma center of our institution. All patients were 
referred to the scleroderma center for clinical presentations of a scleroderma-like 
illness.  
 
 
We compiled a database including the demographics, duration and quality of 
presenting symptoms, laboratory results and  
imaging results for each patient. Data regarding treatment regimens, follow-up, 
and clinical response were also collected, as well as family, social and past 
medical history.  
 
 
The history of each patient’s illness at the time of presentation was documented 
and included the amount of skin involved, the time of onset of symptoms, the 
presence of Raynaud’s phenomenon, contractures, carpal tunnel, and arthritis. 
Any correlation of disease symptoms to strenuous exercise, medication use or 
other potential triggers was documented. At the initial visit, patients were 
examined to assess the distribution, extent, and quality (morphea, p’eau 
d’orange, induration) of skin involvement. Patients were also examined for 
extracutaneous manifestations of eosinophilic fasciitis.  
 
 
Laboratory analysis included complete blood count with leukocyte differential, 
serum protein electrophoresis, rheumatoid factor, antinuclear antibody, creatine 
phosphokinase, aldolase, antitopoisomerase I and anticentromere antibodies, 
sedimentation rate, and C-reactive protein. The results of other studies 
including EMGs, MRIs, 2D echocardiograms, and pulmonary function tests were 
documented when available. Ten patients underwent full thickness skin to 
muscle biopsy to confirm the diagnosis of eosinophilic fasciitis and all slides 
were reviewed by a rheumatologist at our clinic.  
 
 
Treatment was initiated as clinically necessary and each patient’s drug regimen 
was documented as well as any clinical change found at follow up visits. 
Response to therapy was recorded as good when there was more than 40% of 
skin regression based on the total body surface involvement and the modified 
Rodnan skin score, poor when there was continued skin progression, or no effect 
if the skin findings remained the same or had less than 40% skin regression.  
Results  
 
A total of 12 patients were identified with eosinophilic fasciitis at the scleroderma 
center of our institution. Of these, nine were female and three were male. The 
mean age at presentation was 49.8 ± 9.8 years of age. Ten of the patients 
identified themselves as Caucasian and two as African American. The average 
time of diagnosis from the first symptoms of eosinophilic fasciitis was 8.8 ± 6.1 
months (Table 1). For patients with a poor outcome this was 12.5 ± 7.2 months 
while for patients with a good outcome this was 7 ± 4.5 months.  
 
 
All patients had been given other initial diagnoses based on signs that eventually 
led to the diagnosis of eosinophilic fasciitis. The patients studied had visited an 
average of 2.4 physicians, ranging from one to seven, before being referred to our 
clinic and diagnosed with eosinophilic fasciitis. Six patients had an initial 
diagnosis of tendonitis. Of the remaining patients, one was diagnosed with Lyme 
disease, one with fibromyalgia, one with intertigo, and one as a skin 
manifestation of pregnancy. One patient was diagnosed with both tendonitis and 
carpal tunnel syndrome. Only four patients related that their symptoms appeared 
after vigorous exercise. None of our patients reported using products containing 
l-tryptophan or statins. None of our patients had any recent trauma.  
 
 
Upon questioning, five patients admitted to being smokers: two had a 10 pack 
year history, one had a 20 pack year history, and two had a 30 pack year history. 
Past medical history revealed two patients with past diagnoses of cancer, one 
breast and the other chronic lymphocytic leukemia. Half of the patients reported 
a family history of cancer in a first degree relative. Of these patients, four had a 
family history of breast cancer, one ovarian cancer, and one a cardiac cancer.  
Cutaneous manifestations  
 
All patients presented with skin induration (Fig. 1), while seven patients 
displayed peau d’orange and three patients had morphea. The average affected 
total body surface area was 20.1 ± 17.9%. The average skin tightness score based 
on the Modifed Rodnan Skin Score, which is typically used in scleroderma, was 
11.1 ± 7.4 out of a possible maximal score of 51. Eleven patients had lower 
extremity involvement. Upper extremity involvement was seen in nine patients. 
Of these patients, upper extremity involvement affected only the hand in one, 
only the forearm in two, and both forearm and hand in the remaining six (Table 
1).  
 
 
Extracutaneous manifestations  
 
Of the extracutaneous manifestations described in the literature, our patients 
displayed joint contractures, inflammatory arthritis, and carpal tunnel syndrome. 
No patients had experienced Raynaud’s phenomenon or had nailfold 
cappilaroscopy changes. Of the extracutaneous manifestations, joint 
contractures were the most common, affecting eight patients. Of these patients, 
four involved the wrists, three involved the knee, three involved the elbow, two 
involved the ankle, two involved the hand, and one involved the shoulder. Five 
patients were documented as having inflammatory arthritis affecting the feet, 
wrists, and knees. Only two patients had documented carpal tunnel syndrome.  
 
Laboratory analysis  
 
Leukocyte differential was recorded for each patient and hypereosinophilia was 
found in 10 patients. Two patients had eosinophil levels within normal limits. 
The mean initial peripheral eosinophil count was 12 ± 10.7% (absolute eosinophil 
count 1188 ± 1059 cells/L, with a range from 49 to 4059 cells/L). The mean 
absolute eosinophil count in the patients who were diagnosed within 6 months of 
initial symptoms was 1762 cells/L as compared to 784 cells/L in the patients 
who were diagnosed more than 6 months after their initial symptoms though this 
did not reach statistical significance (P = 0.12).  
 
 
Serum protein electrophoresis was documented in all patients, two of which 
had a monoclonal gammopathy. One patient had an elevated IgG lambda, and 
the other an IgA kappa light chain. Rheumatoid factor was only positive in one 
out of the 12 patients tested. Antinuclear antibodies were found in two patients, 
one with a titer of 1 : 80, in a speckled pattern, and one with a titer of 1 : 40 in a 
homogenous pattern. Muscle enzymes documented in all patients were normal. 
All patients had a negative antitopoisomerase I and anticentromere antibodies.  
 
 
EMG studies were performed in six patients and were abnormal in only one 
patient with bilateral carpal tunnel syndrome. Four patients underwent MRI 
studies with only one patient showing findings suggestive of eosinophilic fasciitis. 
This patient showed evidence of disease activity in the right forearm on T2 
weighted MRI images (Fig. 2). Results for 2D echocardiography were reported for 
nine patients, all of which had normal ejection fractions. Right systolic 
ventricular pressure (RSVP) ranged from 20 mmHg to 40 mmHg in these 
patients.  
 
Ten patients underwent full thickness skin to muscle biopsy and histopathology 
of eosinophilic fasciitis was documented including thickened collagen bundles in 
the deep reticular dermis (Figs 3–5).  
 
Seven patients had documented pulmonary function tests, including forced 
expiratory volume (FEV1), forced vital capacity (FVC), total lung capacity (TLC), 
and diffusing capacity (DLCO). The mean FEV1 was 89.5%, ranging from 64 to 
118% of predicted, the mean FVC was 93.2% with a range of 71–106% of 
predicted, the mean TLC was 98.6%, ranging from 75 to 121% of predicted and 
the mean DLCO was 105.9% and ranged from 76 to 147% of predicted.
 
Treatment  
 
All patients received corticosteroids with 10 patients receiving the equivalent to 
prednisone > 20 mg/day as an initial dose, while other medications included 
hydroxychloroquine, topical tacrolimus, methotrexate, sulfasalazine and 
cyclosporine. (Table 2). At a mean follow-up of 17.6 months (range 2– 94 months) 
eight patients had documented marked clinical improvement of cutaneous and 
extracutaneous manifestations and were categorized as having a “good” response 
to therapy. The clinical course for two patients was documented as progressive, 
with quantitative and qualitative progression of the skin manifestions, and were 
categorized as having a “poor” response to therapy. The remaining two patients 
had no change in their presenting cutaneous and extracutaneous manifestations 
after pharmacotherapy, and were labeled as having “no effect” in response to 
treatment (Table 2).  
 
Discussion  
 
Eosinophilic fasciitis is a rare disease characterized by progressive skin 
thickening. Patients report initial swelling and cutaneous thickening, usually 
involving the extremities that can progress to peau d’orange and then 
induration.
2
 Extra-cutaneous manifestations include, joint contractures, 
inflammatory arthritis, restrictive lung disease and pleural effusions.
23 
Monoclonal gammopathy and multiple myeloma have been at times associated 
with eosinophilic fasciitis.
5  
 
 
Currently, full thickness skin to muscle biopsy is the accepted gold standard for 
diagnosing eosinophilic fasciitis. Biopsy typically reveals thickening of the dermis 
due to dense deposition of collagen while the fascia has a lymphocytic and 
eosinophilic infiltrate, especially early on in the disease. The inflammatory 
infiltrate may involve the panniculus and muscle and can lead to fibrinoid 
necrosis (Figs 3–5). Several studies comparing MRI to biopsy have been published 
showing MRI as a useful aid in the diagnosis of eosinophilic fasciitis as well as 
helpful in following a patient’s response to therapy. Both biopsy and MRI show 
evidence of fascial thickening during clinically active disease.
7–9,24  
 
 
Although eosinophilic fasciitis is a rare disease, its clinical manifestations can 
mimic other syndromes. Scleroderma patients present with similar cutaneous 
involvement, making distinction between these two diseases difficult, this further 
complicated by the fact that the treatment of these diseases are similar. Patients 
with early isolated skin involvement may present to a dermatology practice for a 
suspected rash, limiting the cases seen in rheumatology clinics to those patients 
who have extensive skin disease that mimics scleroderma. This in turn suggests 
that cases seen in a dermatology clinic may have more limited skin involvement 
as compared to those patients who are seen in scleroderma clinics. The clinical 
picture of eosinophilic fasciitis may present similarly as a variety of other 
diseases as evidenced by the range of initial diagnoses that were given to the 
patients presented in this study. 
 
Of the 12 patients identified with eosinophilic fasciitis, 75% were female. Some 
studies acknowledge that eosinophilic fasciitis is more common in males
2
 
however, other studies in addition to ours have shown a female predominance.
3
 
The mean age of our patients was 49.8 ± 9.8 years of age which is consistent with 
the mean age reported in other studies.
2  
 
 
The etiology of eosinophilic fasciitis remains unclear. In our study, only four 
patients reported a correlation between symptom onset and intense physical 
exertion. Other studies have documented larger percentages (24 out of 52, and 4 
out of 6) of patients with possible exercise induced eosinophilic fasciitis.
2,8
 None 
of our patients reported using products containing l-tryptophan or statins. None 
of our patients had any recent trauma, while only one patient was previously 
diagnosed with lyme disease.  
 
 
Cutaneous manifestations of eosinophilic fasciitis have been described as 
progressive, with the earliest stage being edema of the extremities, followed by 
peau d’orange with hyperpigmentation, and finally induration.
2
 Interestingly, all 
12 patients in our study had documented skin induration at the time of 
presention. Only seven patients were documented as having peau d’orange. This 
may represent interobserver error. It is also possible that the patients who were 
seen in our clinic presented later in their disease and therefore displayed the 
most advanced stage of cutaneous involvement. Eleven out of 12 patients had 
lower extremity involvement, indicating that this is a commonly affected site. 
Although fewer patients had upper extremity involvement, it was still a site of 
disease in 75% of patients. In our study patients more commonly had 
involvement of both the hand and forearm, however, isolated hand and isolated 
forearm involvement was also documented.  
 
 
Joint contractures were present in two-thirds of the patients studied, with wrist 
being the most commonly involved joint, affecting half of the patients. However, 
several joints were reported to be affected including the ankle, elbow, hand, knee 
and shoulder. Inflammatory arthritis was seen in less than half of the patients 
studied. Both large and small joints were affected, more specifically the hand, 
knee, and wrist.  
 
 
Hypereosinophilia was documented in the majority of our patients, however, two 
patients maintained normal eosinophil counts. This is consistent with the 
previous literature, which indicated that peripheral eosinophilia is not necessary  
to make the diagnosis of eosinophilic fasciitis and does not correlate with the 
clinical severity of the disease.
2
 While the majority of patients did have laboratory 
data indicating hypereosinophilia, only three patients had leukocytosis.  
 
 
Serum protein electrophoresis was performed in each patient, with two patients 
having a monoclonal gammopathy. Abnormal serum protein electrophoresis 
results have been previously reported in the literature.
5  
 
 
MRI has been studied as an alternative means by which to diagnose eosinophilic 
fasciitis as well as to follow the efficacy of treatment. The findings are those of 
fascial thickening, with increased uptake on fluid-sensitive sequences and 
enhancement after IV contrast administration. MRI T2 weighted images showing 
fascial signal hyperintensity describe disease activity while T1 weighted images 
showing fascial thickening describe disease chronicity.
7–9
 While diagnosis is only 
definitive by full-thickness skin to muscle biopsy the potential use of MRI for 
diagnosis appears promising. In our sample, only four patients underwent MRI at 
the time of diagnosis, with only one patient showing MRI evidence of fascial 
thickening. Clinically, this patient had induration of his right forearm, visiualized 
on MRI, and his lower extremeties, as well as peau d’orange of his axilla. 
Interestingly, this patient had the highest eosinophilia count (41%) and believed 
his symptoms were induced by exercise. Unfortunately, this patient did not 
undergo a full thickness skin to muscle biopsy so we were unable to correlate the 
MRI findings to tissue histopathology.  
 
 
While eosinophilic fasciitis is a rare disease, its cutaneous manifestations present 
similarly to other diseases frequently encountered in rheumatology. This raises 
the possibility that the prevalence of eosinophilic fasciitis is higher than has been 
previously documented, with some patients being misdiagnosed. It is therefore 
important to develop a clinical picture of eosinophilic fasciitis in order to 
differentiate it from other syndromes, as well as provide optimal therapy and 
counseling to the patient.  
 
 
Systemic corticosteroids are the mainstay of therapy with a better response in 
those patients who present early and potentially have a more inflammatory 
rather than fibrotic skin lesion. Typical course of therapy is a dose of prednisone 
> 20 mg/day tapered over many months as the disease improves. Other therapies 
have been used either for corticosteroid sparing or for patients not responding to 
this form of therapy. Hydroxychloroquine
2
 histamine 2 antagonists
3,19,25,26 
photochemotherapy
21,22
 immunossupresive agents
18
 and anti-TNF-alpha 
inhibitors
20
 have all been used. Physical therapy should also be initiated early on 
to limit joint contractures and maintain mobility.  
 
 
This study presents clinical, historical, and laboratory information of 12 patients 
with eosinophilic fasciitis. While more data is necessary in order to determine the 
etiology, clinical course, and response to treatment of the disease, we feel that 
the information these 12 patients have provided is a useful addition to the limited 
data that has been published on eosinophilic fasciitis.  
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TABLES & FIGURES 
 
 
 
Table 1  
Eosinophilic Fasciitis patient demographics
 
Characteristics Values 
Age  49.8 ± 9.8 years old  
Gender  9 female/3 male  
Race  10 Caucasian/2 African American  
Time from first symptoms to diagnosis  8.8 ± 6.1 months  
Exercise induced  4/12  
Skin induration  12/12  
Peau d’orange  7/12  
Hands  7/12  
Forearm  8/12  
Lower extremity  11/12  
Total body surface involvement  20.1 ± 17.9%  
Modified Rodnan skin score  
(maximum score = 51) 
11.1 ± 7.4/51  
Joint contractures  2 hand/4 wrist/3 elbow/2 knee/2 
ankle/1 shoulder  
Inflammatory arthritis  5/12  
Malignancy  
2/12 (chronic lymphocytic leukemia, 
breast cancer)  
 
 
 
 
Table 2  
Eosinophilic Fasciitis treatment response  
Patient  Treatment  Follow up  Response  
1  
Hydroxychloroquine 200 mg bid, 
methylprednisolone 20 mg/day with slow 
taper over 4 months 
13 months  Good  
2  
Tacrolimus (topical), hydroxychloroquine 
200 mg bid, prednisone 60 mg/day with 
slow taper over 3 months 
4 months  No effect  
3  Hydroxychloroquine 200 mg bid, 
Prednisone 60 mg/day with slow taper 
over 2 months 
2 months  No effect  
4  Sulfasalazine 500 mg bid, methotrexate 
20 mg/week, Prednisone 10 mg/day for 6 
months 
18 months  Good  
5  
Cyclosporine 75 mg bid for 10 months, 
then methotrexate 25 mg/week for 12 
months, prednisone 60 mg/day tapered 
over 2 months. 
30 months  Good  
6  Methotrexate 20 mg/week for 25 months, 
hydroxychloroquine 200 mg bid for 40 
months, Prednisone 20 mg used early in 
diagnosis on and off for 24 months 
94 months  Good, 
recurred 
2 year 
later 
7  Hydroxychloroquine 200 mg bid for 10 
months, Prednisone 60 mg/day tapered 
over 6 months 
13 months  Good  
8  Prednisone 30 mg/day tapered over 12 
months  
12 months  Poor  
9  Prednisone 30 mg/day tapered over 4 
months  
4 months  Good  
10  
Prednisone 40 mg/day tapered over 4 
months  
4 months  Good  
11  Prednisone 60 mg/day tapered over 4 
months  
4 months  Good  
12  
Dexamethasone 6 mg/day tapered over 
12 months  
12 months  Poor  
 
 
 
 
 
 
 
Figure 1  
 
 Eosinophilic fasciitis related skin induration of the leg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2    
 
T2 weighted MRI of the forearm in a patient with eosinophilic fasciitis.  
*Arrows point to inflammatory changes in the fascia. 
 
 
 
 
 
 
 
Figure 3 
 
Fibrinoid necrosis and lymphocytic infiltration of the fascia (H&E x 100) 
 
 
 
 
Figure 4 
 
Cellular accumulation of lymphocytes and eosinophils in the fascia with 
extension into the panniculus (H&E x 200) 
 
 
 
 
 
 
Figure 5 
Cellular accumulation of lymphocytes and eosinophils in the fascia (H&E x 
400) 
 
 
 
